萬達信息(300168.SZ):原股東萬豪投資被拍賣的1031.4萬股已完成過户
格隆匯10月21日丨萬達信息(300168.SZ)公佈,2021年10月21日,公司根據上海萬豪投資有限公司(“萬豪投資”)管理人發來的《證券過户登記確認書》獲悉,公司原股東萬豪投資於2021年9月13日至14日被拍賣的所持公司股票共計1031.4萬股,已於2021年10月20日完成交割過户手續。此次拍賣完成交割後,萬豪投資已不再是公司的股東。
截至公吿披露日,萬豪投資不持有公司任何股份。公司現第一大股東為中國人壽保險股份有限公司及其一致行動人,萬豪投資的破產清算相關事宜,對公司的生產經營無影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.